Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Aug
10
Today In Oncology
Outreach to HCT Recipients, Primary Care Doctors May Reduce Skin Cancer Risk
American College of Surgeons Commission on Cancer Introduces Rural Cancer Program Accreditation
Phase III Trial Supports Intensified Total Neoadjuvant Therapy in High-Risk Rectal Cancer
Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma
Oral Nicotinamide May Offer Cost-Effective Prevention of Keratinocyte Carcinoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo